natgillin/translations-raw huggingface dataset:
This summary was last updated in November 2018.
Kokkuvõtte viimane uuendus: november 2018.
Sufficient justification for extrapolation of these data to other strains was provided.
Esitati piisavad põhjendused nende andmete ekstrapoleerimiseks teistele tüvedele.
No field studies were conducted.
Väliuuringuid ei teostatud.
These strains belong to four different serotypes (groups) of the virus known as O, A, Asia 1 and SAT2, and are selected, depending on the epidemiological need, from the following eight strains: O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir and SAT2 Saudi Arabia.
Tüved kuuluvad viiruse nelja eri serotüüpi (rühma) - O, A, Asia 1 ja SAT2 - ning need valitakse sõltuvalt epidemioloogilisest vajadusest järgmise kaheksa tüve hulgast: O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir ja SAT2 Saudi Arabia.
This was considered acceptable, given the laboratory data and taking into account that vaccination against foot-and-mouth disease is currently not permitted in the EU under legal controls on foot-and-mouth disease.
Seda peeti vastuvõetavaks, arvestades esitatud laboriandmeid ja võttes arvesse, et vaktsineerimine suu- ja sõrataudi vastu on Euroopa Liidus praegu keelatud suu- ja sõrataudi seaduslike tõrjemeetmete kohaselt.
Further information can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/aftovaxpur-doe.
Lisateave Aftovaxpur DOE kohta on ameti veebilehel: ema.europa.eu/medicines/veterinary/EPAR/aftovaxpur-doe.
When animals are vaccinated at 2 weeks of age, revaccination is recommended at 8 to 10 weeks.
Kui loomad vaktsineeritakse kahe nädala vanuses, on soovitav nad 8-10 nädala vanuselt revaktsineerida.
The measure of effectiveness was the reduction in clinical signs of foot-and-mouth disease.
Efektiivsuse näitaja oli suu- ja sõrataudi kliiniliste sümptomite vähenemine.
Revaccination is required every six months.
Iga kuue kuu järel tuleb loomad revaktsineerida.
The European Medicines Agency decided that Aftovaxpur DOE's benefits are greater than its risks and it be approved for use in the EU.
Euroopa Ravimiamet otsustas, et Aftovaxpur DOE kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
Accidental injection of liquid paraffin may cause severe pain and swelling, particularly if injected into a joint or finger - this could result in the loss of the finger if prompt medical attention is not given.
Vedela parafiini juhuslik süstimine võib põhjustada tugevat valu ja turset, eriti süstimisel liigesesse või sõrme - kui kohest arstiabi ei anta, võib see viia sõrme kaotuseni.
Some studies also looked at the levels of antibodies in cattle, sheep and pigs after single and repeated doses of the vaccine.
Mõnes uuringus vaadeldi ka antikehade sisaldust veistel, lammastel ja sigadel pärast vaktsiini ühekordset või korduvat annustamist.
They usually resolve over a four-week period after vaccination but may last longer in a small number of animals.
See taandub tavaliselt nelja nädala jooksul pärast vaktsineerimist, kuid võib üksikutel loomadel kesta kauem.
If someone is accidentally injected with this product, they must seek medical advice immediately even if only a very small amount is injected.
Juhusliku süstimise korral tuleb otsekohe pöörduda arsti poole, isegi kui süstitud kogus on väga väike.
Aftovaxpur DOE received a marketing authorisation valid throughout the EU on 15 July 2013.
Aftovaxpur DOE müügiluba, mis kehtib kogu Euroopa Liidus, anti 15. juulil 2013.
In the future, if the animals are exposed to foot-and-mouth disease virus, the immune system will be able to produce antibodies more quickly.
Kui loom puutub hiljem suu- ja sõrataudi viirusega uuesti kokku, tekivad antikehad kiiremini.
For more information about using Aftovaxpur DOE, see the package leaflet or contact your veterinarian or pharmacist.
Kui vajate Aftovaxpur DOEga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
Vaccine containing O1 Manisa antigen reduces clinical signs of foot-and-mouth disease in cattle, sheep and pigs.
Antigeeni O1 Manisa sisaldav vaktsiin vähendas veistel, lammastel ja sigadel suu- ja sõrataudi kliinilisi sümptomeid.
In addition, studies in published papers were provided, which examined the effect of vaccination in cattle, sheep, and pigs.
Peale selle esitati avaldatud uuringud, mis käsitlesid vaktsineerimise mõju veistele, lammastele ja sigadele.
The start of protection is 1 week after vaccination in cattle and sheep and 4 weeks after vaccination in pigs.
Veistel ja lammastel saavutatakse kaitse 1 nädal pärast vaktsineerimist ning sigadel 4 nädalat pärast vaktsineerimist.
A slight increase in rectal temperature, of up to 1.2 °C for 4 days, may affect up to 1 in 10 animals following vaccination.
Pärast vaktsineerimist võib kuni 1 loomal 10st rektaaltemperatuur veidi tõusta, st kuni 1,2 °C 4 päeva jooksul.
Other information about Aftovaxpur DOE
Muu teave Aftovaxpur DOE kohta
One, two or four weeks after vaccination animals were exposed to the appropriate strain of live foot-and-mouth disease virus.
Üks nädal või kaks või neli nädalat pärast vaktsineerimist manustati loomadele uuritava suu- ja sõrataudi elusviiruse tüve.
Aftovaxpur DOE contains strains of foot-and-mouth disease virus that have been inactivated so they cannot cause the disease.
Aftovaxpur DOE sisaldab suu- ja sõrataudi viiruse tüvesid, mis on inaktiveeritud, et need ei põhjustaks haigust.
Aftovaxpur DOE is a vaccine used to vaccinate cattle, sheep and pigs from two weeks of age against foot-and-mouth disease.
Aftovaxpur DOE on vaktsiin, mida kasutatakse vähemalt kahe nädala vanuste veiste, lammaste ja sigade vaktsineerimiseks suu- ja sõrataudi vastu.
What is Aftovaxpur DOE and what is it used for?
Mis on Aftovaxpur DOE ja milleks seda kasutatakse?
Aftovaxpur DOE (Foot-and-mouth disease vaccine, killed)
Aftovaxpur DOE (suu- ja sõrataudi vaktsiin, hävitatud)
When it is given to cattle, pigs and sheep, the immune system recognises the virus as ‘foreign' and makes antibodies against it.
Vaktsiini süstimisel veistele, sigadele ja lammastele peab immuunsüsteem viirust võõraks ja tekitab selle vastu antikehi.
The withdrawal period for meat and milk from cattle and sheep and for meat from pigs treated with Aftovaxpur DOE is ‘zero' days which means that there is no mandatory waiting time.
Vaktsiiniga Aftovaxpur DOE vaktsineeritud veiste ja lammaste liha ja piima ning sigade liha keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
The studies showed that Aftovaxpur DOE leads to adequate blood levels of antibodies against foot-andmouth disease strains following a single vaccination.
Uuringud näitasid, et Aftovaxpur DOE tagab ühekordse vaktsineerimise järel suu- ja sõrataudi viiruse tüvede vastaste antikehade piisava sisalduse veres.
Foot-and-mouth disease affects cloven-hoofed animals and causes fever, followed by blisters on the inside of the mouth and on the feet which may rupture and lead to lameness.
Suu- ja sõrataud nakatab sõralisi ja põhjustab palavikku, millele järgneb villide teke suuõõnes ja sõrgade ümbruses.
Aftovaxpur DOE is a vaccine.
Aftovaxpur DOE on vaktsiin.
An overview of Aftovaxpur DOE and why it is authorised in the EU
Aftovaxpur DOE ülevaade ja Euroopa Liidus heakskiitmise põhjused
Aftovaxpur DOE is an emulsion containing liquid paraffin.
Aftovaxpur DOE on vedelat parafiini sisaldav emulsioon.
Aftovaxpur DOE contains up to three strains of inactivated (killed) foot-and-mouth disease virus.
Aftovaxpur DOE on vaktsiin, mis sisaldab suu- ja sõrataudi viiruse kuni kolme inaktiveeritud (hävitatud) tüve.
The vaccine is given to cattle and sheep as an injection under the skin whilst for pigs the injection is given into a muscle.
Vaktsiini manustatakse veistele ja lammastele nahaaluse, sigadele aga lihasesisese süstina.
Aftovaxpur DOE contains an adjuvant (liquid paraffin) to enhance the immune response.
Aftovaxpur DOE sisaldab immuunvastuse tugevdamiseks adjuvanti (vedelat parafiini).
What are the risks associated with Aftovaxpur DOE?
Mis riskid vaktsiiniga Aftovaxpur DOE kaasnevad?
Swellings (up to 12 cm diameter in ruminants and 4 cm in pigs) at the injection site occur in most animals after vaccination.
Enamikul loomadest tekib vaktsineerimise järel süstimiskohas turse (mäletsejatel läbimõõduga kuni 12 cm ning sigadel kuni 4 cm).
What benefits of Aftovaxpur DOE have been shown in studies?
Milles seisneb uuringute põhjal Aftovaxpur DOE kasulikkus?
The range of antibodies produced following vaccination with Aftovaxpur DOE was different from that produced by natural infection; this makes it possible to distinguish vaccinated from infected animals, which is important for disease control.
Vaktsiiniga Aftovaxpur DOE vaktsineerimise järel tekkinud antikehade spekter on loodusliku infektsiooni tagajärjel tekkivast erinev.
How does Aftovaxpur DOE work?
Kuidas Aftovaxpur DOE toimib?
Laboratory studies for the individual strains were conducted in cattle or pigs.
Veistel ja sigadel teostati eri tüvedega laboriuuringuid.
How is Aftovaxpur DOE used?
Kuidas vaktsiini Aftovaxpur DOE kasutatakse?
Aftovaxpur DOE is available as a liquid emulsion for injection and can only be obtained with a prescription.
Vaktsiini Aftovaxpur DOE turustatakse vedela süsteemulsioonina ja see on retseptivaktsiin.
Treatment should be continued long-term.
Ravi peab olema pikaajaline.
At the start of the study patients in both groups had an average score of 10.
Uuringu alguses oli mõlema uuringurühma patsientide keskmine skoor 10.
What measures are being taken to ensure the safe and effective use of Cystadrops?
Mis meetmeid võetakse, et tagada Cystadropsi ohutu ja efektiivne kasutamine?
The score ranges from 0 to 28, with 0 corresponding to no crystals.
Skoorivahemik on 0-28, kus 0 tähendab kristallide puudumist.
These effects are usually mild or moderate and do not last.
Need kõrvalnähud on tavaliselt nõrgad kuni mõõdukad ning ajutised.
The recommended dose is 1 drop in each eye 4 times a day during waking hours.
Soovitatav annus on 1 tilka kummassegi silma 4 korda ööpäevas ärkveloleku ajal.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cystadrops's benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cystadropsi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
Cystadrops mercaptamine
Cystadrops merkaptamiin
The summary of the opinion of the Committee for Orphan Medicinal Products for Cystadrops can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Cystadropsi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The active substance in Cystadrops, mercaptamine, reacts with cystine to dissolve it and to form substances that can be removed from the cells.
Cystadropsis toimeainena sisalduv merkaptamiin reageerib tsüstiiniga, lahustades seda ja moodustades aineid, mida saab rakkudest eemaldada.
The medicine also improved other symptoms of cystinosis such as photophobia.
Ravim leevendas ka muid tsüstinoosi sümptomeid, näiteks fotofoobiat.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cystadrops have been included in the summary of product characteristics and the package leaflet.
Cystadropsi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
Other information about Cystadrops
Muu teave Cystadropsi kohta
The full EPAR for Cystadrops can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst Cystadropsi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Cystadrops.
See on ravimi Cystadrops Euroopa avaliku hindamisaruande kokkuvõte.
The most common side effects with Cystadrops (which may affect more than 1 in 10 people) are related to the eye and include pain, itching and irritation in the eye, increased lacrimation (watering eyes), blurred vision and ocular hyperaemia (red eye).
Cystadropsi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on silmakõrvalnähud, näiteks silmavalu, -sügelus ja -ärritus, suurenenud pisaravoolus, nägemise ähmastumine ja okulaarne hüpereemia (silmapunetus).
What is Cystadrops and what is it used for?
Mis on Cystadrops ja milleks seda kasutatakse?
Cystadrops was shown to be more effective than the comparator at decreasing corneal cystine crystals after 3 months of treatment: in patients using Cystadrops the IVCM score decreased by 4.6 points compared with a decrease of 0.5 points in patients using the comparator.
Uuringus tõendati, et Cystadrops oli 3-kuulise ravi järel sarvkestas esinevate tsüstiinikristallide sisalduse vähendamisel võrdlusravimist efektiivsem: IVCM-skoor vähenes Cystadropsi uuringurühma patsientidel 4,6 punkti võrra ja see vähenes võrdlusravimi rühmas 0,5 punkti võrra.
It is not intended to provide practical advice on how to use Cystadrops.
Hindamisaruandes ei anta Cystadropsi kasutamise praktilisi nõuandeid.
Because the number of patients with cystinosis is low, the disease is considered ‘rare', and Cystadrops was designated an ‘orphan medicine' (a medicine used in rare diseases) on 7 November 2008.
Et tsüstinoosiga patsientide arv on väike ja see haigus esineb harva, nimetati Cystadrops 7. novembril 2008 harvikravimiks.
Damage from the build-up of cystine crystals inside the cells of the cornea can cause serious vision problems.
Sarvkesta rakkudesse kogunenud tsüstiinikristallide tekitatavad kahjustused võivad põhjustada raskeid nägemisprobleeme.
Cystinosis is an inherited disease where a natural substance called cystine builds up in the body forming damaging crystals, particularly in the kidneys and cornea (the transparent layer in front of the eye).
Tsüstinoos on pärilik haigus, mille korral organismi koguneb looduslikku ainet tsüstiini, tekitades kahjustavaid kristalle, eelkõige neerudes ja sarvkestas (läbipaistev kiht silma eesosas).
For practical information about using Cystadrops, patients should read the package leaflet or contact their doctor or pharmacist.
Kui vajate Cystadropsi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
Why is Cystadrops approved?
Miks Cystadrops heaks kiideti?
Treatment with Cystadrops also led to reductions in photophobia (eye discomfort in bright light).
Cystadropsi-raviga vähenes ka fotofoobia (valguskartus, silma ebamugavustunne eredas valguses).
For more information about treatment with Cystadrops, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Cystadropsiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
When it is applied to the eye, the amount of cystine in the cells of the cornea decreases, limiting damage to the eye.
Ravimi manustamisel silma väheneb sarvkesta rakkudes sisalduva tsüstiini kogus, mis vähendab silmakahjustusi.
What are the risks associated with Cystadrops?
Mis riskid Cystadropsiga kaasnevad?
The doctor may decrease the dose progressively to 1 drop a day depending on the results of eye examinations.
Arst võib silmade seisundi kontrollimise tulemusel vähendada annust järkjärgult 1 tilgani ööpäevas.
How is Cystadrops used?
Kuidas Cystadropsi kasutatakse?
Cystadrops contains the active substance mercaptamine (also known as cysteamine).
Cystadrops sisaldab toimeainena merkaptamiini (tsüsteamiini).
For the full list of all side effects and restrictions with Cystadrops, see the package leaflet.
Cystadropsi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
The main measure of effectiveness was based on the reduction in corneal cystine crystals as seen under the microscope and quantified using a score called the IVCM score.
Efektiivsuse põhinäitaja oli sarvkesta mikroskoopuuringus nähtavate tsüstiinikristallide sisalduse vähenemine, mida mõõdeti IVCM-skooriga.
Cystadrops is an eye medicine used in patients from 2 years of age who have cystinosis.
Cystadrops on silmaravim, mis on näidustatud vähemalt 2-aastastele patsientidele tsüstinoosi raviks.
In addition, Cystadrops has been shown in a study to be effective at decreasing corneal cystine crystals.
Lisaks on uuringuga tõendatud, et Cystadrops on efektiivne sarvkestas esinevate tsüstiinikristallide sisalduse vähendamisel.
Regarding safety, although side effects related to the eye are very common, they are usually manageable.
Kuigi Cystadropsi silmakõrvalnähud on väga tavalised, on need tavaliselt talutavad.
Cystadrops is available as eye drops.
Cystadropsi turustatakse silmatilkadena.
Cystadrops can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in the management of cystinosis.
Ravi peab alustama tsüstinoosi ravis kogenud arsti järelevalve all.
How does Cystadrops work?
Kuidas Cystadrops toimib?
What benefits of Cystadrops have been shown in studies?
Milles seisneb uuringute põhjal Cystadropsi kasulikkus?
Cystadrops is used to reduce the build-up of cystine crystals in the cornea.
Cystadropsiga vähendatakse tsüstiinikristallide kogunemist sarvkesta.
Mercaptamine eye drop solutions made up locally in pharmacies or hospitals have been used for many years for the management of eye symptoms of cystinosis.
Tsüstinoosi silmasümptomite raviks on aastaid kasutatud merkaptamiini sisaldavaid silmatilkade lahuseid, mida valmistatakse kohapeal apteegis.
Cystadrops has been compared with another less concentrated mercaptamine eye drop solution in one main study involving 32 patients from 2 years of age with cystinosis.
Cystadropsi võrreldi ühes põhiuuringus teise, väiksemas kontsentratsioonis merkaptamiini sisaldava silmatilkade lahusega.
It is available as tablets (50 and 150 mg).
Seda turustatakse tablettidena (50 mg ja 150 mg).
The tablets must always be taken after the patient has fasted overnight for at least six hours and at least 30 minutes before the first food or drink of the day.
Tablett tuleb alati võtta siis, kui patsient ei ole öösel vähemalt 6 tundi midagi söönud ning vähemalt 30 minutit enne päeva esimest toidu- ja joogikorda.
The full EPAR for Ibandronic Acid Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Euroopa avaliku hindamisaruande täistekst Ibandronic Acid Teva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
For treating osteoporosis, one 150-mg tablet is taken once a month.
Osteoporoosi raviks võetakse üks 150 mg tablett üks kord kuus.
Patients should also take vitamin D and calcium supplements if they do not get enough from their diet.
Kui patsient ei saa toidust piisavalt kaltsiumi ja D-vitamiini, tuleb võtta täiendavalt neid sisaldavaid preparaate.
The European Commission granted a marketing authorisation valid throughout the EU for Ibandronic Acid Teva on 17 September 2010.
Euroopa Komisjon andis Ibandronic Acid Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. septembril 2010.
Ibandronic Acid Teva must be taken with a full glass of plain water (but not mineral water) while standing or sitting up, and the tablets should not be chewed, sucked or crushed.
Ibandronic Acid Tevat tuleb võtta klaasi veega (kuid mitte mineraalveega) seistes või istudes.
For more information about treatment with Ibandronic Acid Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Ibandronic Acid Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
This means that Ibandronic Acid Teva is similar to a ‘reference medicine' already authorised in the European Union (EU).
See tähendab, et Ibandronic Acid Teva on sarnane võrdlusravimiga, millel juba on Euroopa Liidus müügiluba.
Ibandronic Acid Teva 50 mg is used to prevent ‘skeletal events' (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).
Ibandronic Acid Teva 50 mg annust kasutatakse luukahjustuste (luumurrud või ravi vajavad luutüsistused) ennetamiseks rinnavähi ja luumetastaasidega (kui vähk on levinud luudesse) patsientidel.
For the prevention of skeletal events, one 50-mg tablet is taken once a day.
Luukahjustuste ennetamiseks võetakse üks 50 mg tablett üks kord ööpäevas.
The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases and in women with osteoporosis.
Luukoe lagundamist peatades muudab ravim luud murdudele vastupidavamaks, millega saab ennetada luumurde luumetastaasidega vähipatsientidel ja osteoporoosiga naistel.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Teva.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
The CHMP concluded that, in accordance with EU requirements, Ibandronic Acid Teva has been shown to have comparable quality and to be bioequivalent to Bondronat and Bonviva.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Ibandronic Acid Teva võrreldav kvaliteet ja bioekvivalentsus ravimitega Bondronat ja Bonviva.
Because Ibandronic Acid Teva is a generic medicine and is bioequivalent to the reference medicines, its benefits and risks are taken as being the same as the reference medicines's.
Et Ibandronic Acid Teva on geneeriline ravim ja võrdlusravimitega bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimitel.
This is a summary of the European public assessment report (EPAR) for Ibandronic Acid Teva.
See on ravimi Ibandronic Acid Teva Euroopa avaliku hindamisaruande kokkuvõte.
Ibandronic Acid Teva 150 mg is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of developing bone fractures.
Ibandronic Acid Teva 150 mg annust kasutatakse osteoporoosi (luu-urbnemuse) raviks menopausijärgses eas naistel, kellel luumurru tekke risk on suurenenud.
The Committee recommended that Ibandronic Acid Teva be given marketing authorisation.
Komitee soovitas anda Ibandronic Acid Teva müügiloa.
The tablet must always be taken after an overnight fast, one hour before any food or drink except for water.
Tablett tuleb alati võtta siis, kui patsient ei ole öösel midagi söönud ning vähemalt üks tund enne toidu- ja joogikorda (v.a vee joomine).
The reference medicines for Ibandronic Acid Teva are Bondronat and Bonviva.
Ibandronic Acid Teva võrdlusravimid on Bondronat ja Bonviva.
Therefore, the CHMP's view was that, as for Bondronat and Bonviva, the benefit outweighs the identified risk.
Seetõttu on inimravimite komitee arvamusel, et nagu ka Bondronati ja Bonviva korral, ületab Ibandronic Acid Teva kasulikkus sellega kaasnevad riskid.
Ibandronic Acid Teva ibandronic acid
Ibandronic Acid Teva ibandroonhape
Because Ibandronic Acid Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicines.
Et Ibandronic Acid Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Ibandronic Acid Teva bioekvivalentsust võrdlusravimitega.
Ibandronic Acid Teva is a medicine that contains the active substance ibandronic acid.
Ibandronic Acid Teva on ravim, mis sisaldab toimeainena ibandroonhapet.